PIUR IMAGING, a pioneering medical device company at the forefront of AI-powered tomographic 3D ultrasound, has successfully closed a €5.6 million growth capital funding round. This investment, led by Aescuvest Capital Partners, a prominent healthcare investment firm, will accelerate the commercialization of PIUR’s innovative imaging solutions across the USA and Europe.
PIUR IMAGING is transforming diagnostic workflows with the industry’s first vendor-agnostic, FDA-cleared, and CE-marked tomographic 3D ultrasound solution. Their proprietary sensor technology seamlessly converts standard 2D ultrasound systems into high-performance 3D imaging platforms, allowing clinicians to capture entire organs and anatomical structures in a single, comprehensive scan. This advancement, combined with AI-based image analysis and volumetric measurements, empowers faster, more objective, and highly reproducible diagnoses across a wide array of clinical applications.
Redefining ultrasound diagnostics
Headquartered in Vienna with offices in Munich and Cambridge (MA), PIUR IMAGING is an ISO-13485 certified and FDA-cleared medical device company specializing in advanced tomographic 3D ultrasound solutions. The company’s mission is to improve diagnostic workflows and enhance patient care by offering innovative add-on solutions for existing ultrasound devices, empowering clinicians with accurate, reproducible imaging for optimal patient outcomes.
“Ultrasound is one of the most valuable imaging modalities—flexible, safe, and affordable. But its greatest limitation remains user-dependency, as most conclusions are drawn from 2D slices that vary by operator,” said Frederik Bender, Managing Director & CEO of PIUR IMAGING. “By adding a third dimension, we eliminate much of that variability—shifting from subjective snapshots to comprehensive, organ-level imaging that enables AI to perform more consistent and reliable analysis. This investment allows us to bring this vision to scale. It empowers us to grow our commercial footprint, especially in the U.S., expand our product integration with global ultrasound leaders, and continue developing clinical applications that improve patient outcomes.”
Following recent FDA clearance and the establishment of a U.S. subsidiary, the new funding will primarily fuel the company’s commercial expansion in the United States. This growth will be propelled by two key products: PIUR tUS Infinity, a vendor-neutral add-on that upgrades any existing 2D ultrasound to 3D capabilities, and PIUR tUS inside, an integrated solution directly embedded into select GE HealthCare LOGIQ™ scanners.
“PIUR’s approach is brilliantly simple. Instead of reinventing the entire system, they unlock new value from existing ultrasound devices with a seamless add-on solution,” states Christoph Bartoschek, Partner & Head of Investment at Aescuvest Capital Partners. “This significantly lowers the adoption barrier – users grasp it immediately, and the clinical benefits are undeniable.”
Bartoschek adds, “What truly excites us as investors is the clarity of their value proposition and the company’s robust foundation. PIUR has already built a loyal customer base in the DACH region, secured agreements with respected partners in the imaging ecosystem, and assembled a team with a clear vision for scaling across clinical indications and geographies. The recent FDA clearance of tUS inside makes this an ideal investment opportunity, perfectly aligning with our strategy of targeting companies approaching pivotal regulatory milestones.”
With this strategic investment, PIUR IMAGING is poised to accelerate its evolution from a European innovator to a global leader. By combining clinical-grade technology, strong regulatory foundations, and a scalable business model, the company is uniquely positioned to meet the escalating demand for intelligent, cost-effective imaging solution.
